Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party.

MLA

Jung, Sung-Hoon, et al. “Efficacy and Safety of Blinatumomab Treatment in Adult Korean Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia on Behalf of the Korean Society of Hematology ALL Working Party.” Annals of Hematology, vol. 98, no. 1, Jan. 2019, pp. 151–58. EBSCOhost, https://doi.org/10.1007/s00277-018-3495-2.

APA

Jung, S.-H., Lee, S.-R., Yang, D.-H., Lee, S., Yoon, J.-H., Lee, H., Bang, S.-M., Koh, Y., Park, S., Kim, D. S., Yhim, H.-Y., Kim, S.-H., Lee, J.-H., Sohn, S. K., Song, I.-C., Lee, H.-G., Cheong, J.-W., Choi, Y., & Shin, H.-J. (2019). Efficacy and safety of blinatumomab treatment in adult Korean patients with relapsed/refractory acute lymphoblastic leukemia on behalf of the Korean Society of Hematology ALL Working Party. Annals of Hematology, 98(1), 151–158. https://doi.org/10.1007/s00277-018-3495-2

Chicago

Jung, Sung-Hoon, Se-Ryeon Lee, Deok-Hwan Yang, Seok Lee, Jae-Ho Yoon, Hyewon Lee, Soo-Mee Bang, et al. 2019. “Efficacy and Safety of Blinatumomab Treatment in Adult Korean Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia on Behalf of the Korean Society of Hematology ALL Working Party.” Annals of Hematology 98 (1): 151–58. doi:10.1007/s00277-018-3495-2.